Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Lisa Licitra et al.|The Lancet|2018Cited by 1.7k
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus PaperBernhard Wörmann, Ralf‐Dieter Hofheinz, Carsten Bokemeyer et al.|Oncology Research and Treatment|2020Cited by 88